Using machine learning tools to detect gene mutations from leukemia cell images
Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...
Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
Targeted Oncology2d
Actimab-A Triplet Trial Launches in Frontline AML
Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...
Targeted Oncology1d
Organ-Sparing TMLI Enhances AML Transplant Outcomes
Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...
Clinical Trials Arena on MSN1d
Cantargia enrols first patient in trial of nadunolimab for AML and MDS
Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...
The American Journal of Managed Care12h
Neutrophil Subset Changes Give Insight Into First Mechanisms of MDS, AML
The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density neutrophil subsets in myelodysplastic syndromes (MDS), acute myeloid leukemia ...
Cracking cancer's code: Research identifies novel drug target for acute myeloid leukemia treatment
Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at ...
First Patient Enrolled in Cantargia's Leukemia Study with nadunolimab
Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq ...
Medscape7d
AML: Monitor Early Measurable Residual Disease to Optimize Outcomes
Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.
Bionano Announces Publication Reporting First Use of OGM to Detect Chromoanagenesis, a Key Marker of Poor Prognosis in AML
Bionano will host a webinar featuring the study’s lead author, Dr. Guilin Tang, who will discuss the study and its findings in ...